Literature DB >> 12691636

Matrix metalloproteinase in left ventricular remodeling and heart failure.

Suresh Shastry1, Melvin R Hayden, Pamela A Lucchesi, Suresh C Tyagi.   

Abstract

Accumulation of oxidized matrix between the endothelium and cardiac muscle, and endocardial endothelial dysfunction, are the hallmarks of congestive heart failure. The induction of oxidative stress, decrease in endothelial cell density, activation of matrix and disintegrin metalloproteinase, collagenolysis, and repression of cardiac inhibitor of metalloproteinase (CIMP) are associated with deposition of oxidized matrix. Studies that employ CIMP as genetic or proteomic therapeutic agent may improve the heart's response to nitric oxide donors. Identification of major players involved in the control of oxidative and proteolytic stresses that ameliorate matrix deposition by integrin shading will help to develop strategies to prevent congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12691636     DOI: 10.1007/s11886-003-0049-5

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  50 in total

1.  Arteriogenesis: Angiogenesis within Unstable Atherosclerotic Plaque-- Interactions with Extracellular Matrix.

Authors: 
Journal:  Curr Interv Cardiol Rep       Date:  2000-08

2.  Oxidant-mediated inactivation of TIMP.

Authors:  G P Stricklin; J R Hoidal
Journal:  Matrix Suppl       Date:  1992

3.  Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis.

Authors:  A H Baker; A B Zaltsman; S J George; A C Newby
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

4.  The serine protease inhibitor antithrombin III inhibits LPS-mediated NF-kappaB activation by TLR-4.

Authors:  A Mansell; A Reinicke; D M Worrall; L A O'Neill
Journal:  FEBS Lett       Date:  2001-11-23       Impact factor: 4.124

5.  Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice.

Authors:  L E Rohde; A Ducharme; L H Arroyo; M Aikawa; G H Sukhova; A Lopez-Anaya; K F McClure; P G Mitchell; P Libby; R T Lee
Journal:  Circulation       Date:  1999-06-15       Impact factor: 29.690

6.  Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats.

Authors:  Amanda Miller; Vibhas Mujumdar; Lena Palmer; John D Bower; Suresh C Tyagi
Journal:  Am J Hypertens       Date:  2002-02       Impact factor: 2.689

7.  Myocyte/capillary mismatch in the heart of uremic patients.

Authors:  K Amann; M Breitbach; E Ritz; G Mall
Journal:  J Am Soc Nephrol       Date:  1998-06       Impact factor: 10.121

8.  Regenerating functional myocardium: improved performance after skeletal myoblast transplantation.

Authors:  D A Taylor; B Z Atkins; P Hungspreugs; T R Jones; M C Reedy; K A Hutcheson; D D Glower; W E Kraus
Journal:  Nat Med       Date:  1998-08       Impact factor: 53.440

9.  Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite.

Authors:  E R Frears; Z Zhang; D R Blake; J P O'Connell; P G Winyard
Journal:  FEBS Lett       Date:  1996-02-26       Impact factor: 4.124

10.  The role of nitric oxide and metalloproteinases in the pathogenesis of hyperoxia-induced lung injury in newborn rats.

Authors:  A Radomski; G Sawicki; D M Olson; M W Radomski
Journal:  Br J Pharmacol       Date:  1998-12       Impact factor: 8.739

View more
  1 in total

1.  Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice.

Authors:  Stephane Heymans; Florea Lupu; Sven Terclavers; Bjorn Vanwetswinkel; Jean-Marc Herbert; Andrew Baker; Desire Collen; Peter Carmeliet; Lieve Moons
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.